Bryan Johnson
"Blueprint is a stock ticker of sorts that will reveal, through the tracking of my biological versus chronological age, the status of today's anti-aging science (even if an N=1 for now)."
Bryan Johnson founded the payments company Braintree in 2007 and sold it, along with the Venmo app it had acquired, to PayPal for $800 million in September 2013 (TechCrunch, 26 September 2013); Johnson has said his own after-tax take was $300 million (Hampton interview, 28 February 2025). He used part of the proceeds to found OS Fund, a venture-capital firm, with a reported $100 million of his own capital in 2014 (Forbes, 15 September 2015), and Kernel, a brain-monitoring hardware company, into which he announced investing $100 million of his own money at its 2016 founding (TechCrunch, 20 October 2016). On 13 October 2021 he announced Project Blueprint, an attempt to measure and reduce the “biological age” of his organs using a large personal medical and research team; the project became the commercial company Blueprint. Johnson is both the intervention’s developer and its primary evidence source: the biomarker results he publishes from his own body are the central marketing material for a product line he founded and continues to promote. He has repeatedly and publicly abandoned specific components of his own protocol after reporting no benefit or adverse effects, including a young-plasma exchange regimen (discontinued July 2023), growth-hormone supplementation (discontinued after roughly 100 days), and rapamycin (also discontinued) — a self-correcting pattern that distinguishes this case from historical practitioners who never revised their own claims.